Dalbavancin, Oritavancin and Telavancin

Dalbavancin (Dalvance), oritavancin (Orbactiv/Kimyrsa) and telavancin (Vibativ) are semisynthetic lipoglycopeptides built on a glycopeptide backbone with a lipid side chain. They are bactericidal against susceptible Gram-positive organisms, including MRSA. Telavancin was US-approved in 2009; dalbavancin and oritavancin followed in 2014.

Like vancomycin, the drugs bind D-alanyl-D-alanine cell-wall precursor termini and inhibit wall formation. Their lipid tails anchor in bacterial membranes; oritavancin and telavancin additionally disrupt the membrane itself.

Dalbavancin’s approximately two-week half-life supports weekly or single-dose regimens, and oritavancin can treat a skin infection with one infusion. Telavancin is given daily. In the pivotal program, two once-weekly dalbavancin doses were noninferior to conventional vancomycin followed by linezolid for skin infection. Duration and route convenience do not make all three drugs equivalent.

All are used for susceptible Gram-positive skin infections. Dalbavancin and oritavancin can avoid prolonged IV-line courses when a brief regimen is advantageous. Telavancin’s additional pneumonia role is reserved for specified circumstances, not a class-wide indication.

Common effects include nausea, headache and diarrhea. Dalbavancin may raise liver enzymes; telavancin can cause taste disturbance and foamy urine. Infusion-related reactions can occur.

Telavancin has boxed warnings for nephrotoxicity and fetal harm and requires pregnancy testing before use. Pneumonia patients with pre-existing moderate/severe renal impairment had higher mortality. Oritavancin interferes with some coagulation tests and cannot be combined with IV unfractionated heparin for a period after dosing. These product-specific restrictions must not be generalized or omitted.